Rituximab-induced direct inhibition of T-cell activation

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1233-1241

  Stroopinsky, Dina ^a   Katz, Tamar ^a,b   Rowe, Jacob M ^a,b   Melamed, Doron ^b   Avivi, Irit ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Infections; Non Hodgkin lymphoma; Rituximab; T cell inactivation

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CELL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ADULT; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL SEPARATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84865713557     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1168-2     Document Type: Article

References (33)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833 (Pubitemid 28363048)
2. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6: 394-403
3. Keating GM (2010) Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445-1476
4. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-Term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853-2858
5. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190
6. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M (2010) Long-Term followup of patients with follicular lymphoma receiving single-Agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484
7. Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15:e2-e16
8. Kurokawa T, Hase M, Tokuman N, Yoshida T (2011) Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 29:5-9
9. Stroopinsky D, Avivi I, Rowe JM, Avigan D, Katz T (2009) Allogeneic induced human FOXP3(?)IFN-gamma(?) T cells exhibit selective suppressive capacity. Eur J Immunol 39:2703-2715
10. Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M (2006) Serum levels and pharmacokinetic of rituximab in Bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. J Clin Oncol 24:7537a
11. Pfreundschuh M, Zeynalova S, Poeschel V, Haenel M, Schmitz N, Hensel M, Reiser M, Loeffler M, Schubert J (2007) Dosedense rituximab improves outcome of elderly patients with poorprognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL). Blood 110:789a
12. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834-4840
13. Koo YX, Tan DS, Tan IB, Tao M, Lim ST (2009) Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 150:655-656
14. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4:599-608 (Pubitemid 40723731)
15. Chang H, Yeh HC, Su YC, Lee MH (2008) Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. J Chin Med Assoc 71: 579-582
16. Pfreundschuh M, Poeschel V, Haenel M, Schmitz N, Ho AD, Reiser M, Loeffler M, Schubert J (2008) Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL). J Clin Oncol 26:8508a
17. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS (2010) High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, Adriamycin, vincristine, and prednisone. Leuk Lymphoma 51: 797-801
18. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D (2007) Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139-140 (Pubitemid 46232678)
19. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R (2008) Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 80:275-276 (Pubitemid 351253467)
20. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, Pistello M, Antonioli L, Fornai M, Pepe P, Rossi G, Petrini M (2010) Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 15:1214-1219
21. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY (2011) Rituximab-Associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-Analysis and examination of FDA safety reports. Ann Oncol 22:1170-1180
22. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-Targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581 (Pubitemid 38758544)
23. Liossis SN, Sfikakis PP (2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127:280-285
24. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF (2007) Therapeutic B cell depletion impairs adaptive and autoreactive CD4? T cell activation in mice. Proc Natl Acad Sci USA 104:20878-20883
25. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M (2008) Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 128:2850-2858
26. Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stuve O, Shlomchik M, Eagar TN (2011) Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 6:e17103
27. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, Wilke N, Schmidt RE, Jacobs R (2009) Depletion of functionally active CD20? T cells by rituximab treatment. Arthritis Rheum 60:3563-3571
28. Hultin LE, Hausner MA, Hultin PM, Giorgi JV (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14:196-204 (Pubitemid 23042743)
29. Tsokos GC (2004) B cells, be gone-B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 350:2546-2548 (Pubitemid 38758541)
30. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2? conductance found constitutively in B lymphocytes. J Cell Biol 121:1121-1132 (Pubitemid 23154272)
31. Li H, Ayer LM, Lytton J, Deans JP (2003) Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 278: 42427-42434 (Pubitemid 37310514)
32. Rodriguez J, Gutierrez A (2008) Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 3:22-30 (Pubitemid 351276813)
33. Unruh TL, Zuccolo J, Beers SA, Kanevets U, Shi Y, Deans JP (2010) Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors. J Immunother 33:30-39